News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Axel Grothey, MD, West Cancer Center, University of Tennessee

Articles by Axel Grothey, MD, West Cancer Center, University of Tennessee

Educational Tools for Possible Drug-Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Management of Patients Who Develop ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Changes in Treatment Goals due to Drug Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Risk of ILD as a Class Effect and Identifying ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Risks for Developing ILD in Gastrointestinal Cancer Studies

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Role of Antibody Drug Conjugates and Personal Experience

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Patient Management and Educational Tools for ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Identifying Drug-Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Rate of ILD and Monitoring Parameters

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Personal Experience with Drug-Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Potential Risk of Drug-Induced Interstitial Lung Disease

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Patient Management upon Developing ILD and Education

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Patient Factors for Developing ILD and Personal Experience

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Managing Patient Symptoms and Clinician Education

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

CDK 4/6 Inhibitors and Identifying ILD in Patients

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Rate and Class Effect of ILD with Antibody Drug Conjugates

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Use of Antibody Drug Conjugates and Potential for ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Changes in Cancer Treatment and Management of ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Risks for Developing ILD and Personal Experience

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Antibody Drug Conjugates and Interstitial Lung Disease Risk

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

Latest Updated Articles

Identifying Drug-Induced ILD
Published: June 30th 2020 | Updated:
Educational Tools for Possible Drug-Induced ILD
Published: June 30th 2020 | Updated:
Use of Antibody Drug Conjugates and Potential for ILD
Published: June 30th 2020 | Updated:
Risks for Developing ILD in Gastrointestinal Cancer Studies
Published: June 30th 2020 | Updated:
Changes in Cancer Treatment and Management of ILD
Published: June 30th 2020 | Updated:
Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials
Published: June 30th 2020 | Updated:

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies